Literature DB >> 29037996

Synthesis, anti-cancer screening and tyrosyl-DNA phosphodiesterase 1 (Tdp1) inhibition activity of novel piperidinyl sulfamides.

Jung Ho Jun1, Vineet Kumar2, Thomas S Dexheimer3, Iwona Wedlich4, Marc C Nicklaus4, Yves Pommier3, Sanjay V Malhotra5.   

Abstract

Novel piperidinyl-based sulfamide derivatives were designed and synthesized through various synthetic routes. Anticancer activities of these sulfamides were evaluated by phenotypic screening on National Cancer Institute's 60 human tumor cell lines (NCI-60). Preliminary screening at 10μM concentration showed that piperidinyl sulfamide aminoester 26 (NSC 749204) was sensitive to most of the cell lines in the panel. Further dose-response studies showed that 26 was highly selective for inhibition of colon cancer cell lines with minimum GI50=1.88μM for COLO-205 and maximum GI50=11.1μM for SW-620 cells. These newly synthesized sulfamides were also screening for their Tdp1 inhibition activity. Compound 18 (NSC 750706) showed significant inhibition of Tdp1 with IC50=23.7μM. Molecular-docking studies showed that 18 bind to Tdp1 in its binding pocket similar to a known Tdp1 inhibitor.
Copyright © 2017. Published by Elsevier B.V.

Entities:  

Keywords:  Anti-cancer; Biological activity; Piperidinyl sulfamides; Synthesis; Tyrosyl-DNA phosphodiesterase 1 (Tdp1)

Mesh:

Substances:

Year:  2017        PMID: 29037996      PMCID: PMC8087116          DOI: 10.1016/j.ejps.2017.10.017

Source DB:  PubMed          Journal:  Eur J Pharm Sci        ISSN: 0928-0987            Impact factor:   4.384


  30 in total

Review 1.  DNA topoisomerases and their poisoning by anticancer and antibacterial drugs.

Authors:  Yves Pommier; Elisabetta Leo; HongLiang Zhang; Christophe Marchand
Journal:  Chem Biol       Date:  2010-05-28

Review 2.  Doripenem: a new carbapenem antibiotic.

Authors:  Elias B Chahine; Mary J Ferrill; Mara N Poulakos
Journal:  Am J Health Syst Pharm       Date:  2010-12-01       Impact factor: 2.637

Review 3.  DNA topoisomerases.

Authors:  J C Wang
Journal:  Annu Rev Biochem       Date:  1996       Impact factor: 23.643

4.  Corrigendum to “Inhibitors of human tyrosyl-DNA phospodiesterase (hTdp1) developed by virtual screening using ligand-based pharmacophores” [Bioorg. Med. Chem. 18 (2010) 182–189]

Authors:  Iwona E Weidlich; Thomas Dexheimer; Christophe Marchand; Smitha Antony; Yves Pommier; Marc C Nicklaus
Journal:  Bioorg Med Chem       Date:  2010-03-15       Impact factor: 3.641

5.  The sulfamide motif in the design of enzyme inhibitors.

Authors:  Jean-Yves Winum; Andrea Scozzafava; Jean-Louis Montero; Claudiu T Supuran
Journal:  Expert Opin Ther Pat       Date:  2006-01       Impact factor: 6.674

Review 6.  Topoisomerase I inhibitors: camptothecins and beyond.

Authors:  Yves Pommier
Journal:  Nat Rev Cancer       Date:  2006-10       Impact factor: 60.716

Review 7.  Quinagolide--a valuable treatment option for hyperprolactinaemia.

Authors:  Anne Barlier; Philippe Jaquet
Journal:  Eur J Endocrinol       Date:  2006-02       Impact factor: 6.664

8.  Efficient synthesis of beta2-amino acid by homologation of alpha-amino acids involving the Reformatsky reaction and Mannich-type imminium electrophile.

Authors:  Roba Moumne; Solange Lavielle; Philippe Karoyan
Journal:  J Org Chem       Date:  2006-04-14       Impact factor: 4.354

9.  Carbonic anhydrase inhibitors: the X-ray crystal structure of the adduct of N-hydroxysulfamide with isozyme II explains why this new zinc binding function is effective in the design of potent inhibitors.

Authors:  Claudia Temperini; Jean-Yves Winum; Jean-Louis Montero; Andrea Scozzafava; Claudiu T Supuran
Journal:  Bioorg Med Chem Lett       Date:  2007-02-28       Impact factor: 2.823

10.  4-Pregnen-21-ol-3,20-dione-21-(4-bromobenzenesulfonate) (NSC 88915) and related novel steroid derivatives as tyrosyl-DNA phosphodiesterase (Tdp1) inhibitors.

Authors:  Thomas S Dexheimer; Lalji K Gediya; Andrew G Stephen; Iwona Weidlich; Smitha Antony; Christophe Marchand; Heidrun Interthal; Marc Nicklaus; Robert J Fisher; Vincent C Njar; Yves Pommier
Journal:  J Med Chem       Date:  2009-11-26       Impact factor: 7.446

View more
  4 in total

1.  Investigation on the Anticancer Activity of Symmetric and Unsymmetric Cyclic Sulfamides.

Authors:  Jaden Jungho Jun; Divya Duscharla; Ramesh Ummanni; Paul R Hanson; Sanjay V Malhotra
Journal:  ACS Med Chem Lett       Date:  2021-01-15       Impact factor: 4.345

2.  Targeting Tyrosyl-DNA phosphodiesterase I to enhance toxicity of phosphodiester linked DNA-adducts.

Authors:  Evan J Brettrager; Robert C A M van Waardenburg
Journal:  Cancer Drug Resist       Date:  2019-12-19

3.  Synthesis, Spectroscopic Characterization, and In Vitro Antibacterial Evaluation of Novel Functionalized Sulfamidocarbonyloxyphosphonates.

Authors:  Abdeslem Bouzina; Khaoula Bechlem; Hajira Berredjem; Billel Belhani; Imène Becheker; Jacques Lebreton; Marc Le Borgne; Zouhair Bouaziz; Christelle Marminon; Malika Berredjem
Journal:  Molecules       Date:  2018-07-10       Impact factor: 4.411

4.  A Dual-Sensor-Based Screening System for In Vitro Selection of TDP1 Inhibitors.

Authors:  Ann-Katrine Jakobsen; Josephine Geertsen Keller; María Gonzalez; Endika Martin-Encinas; Francisco Palacios; Concepcion Alonso; Birgitta Ruth Knudsen; Magnus Stougaard
Journal:  Sensors (Basel)       Date:  2021-07-15       Impact factor: 3.576

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.